Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $5.00.

A number of analysts have recently commented on the stock. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Wedbush restated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Morgan Stanley decreased their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Finally, Leerink Partners reiterated a “market perform” rating and set a $2.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th.

Zentalis Pharmaceuticals Stock Up 4.6%

Shares of NASDAQ:ZNTL opened at $2.93 on Wednesday. The firm has a market cap of $211.70 million, a price-to-earnings ratio of -1.42 and a beta of 1.75. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.95. The company’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $1.66.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. Research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Group Walters acquired 6,459,973 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was bought at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the acquisition, the insider owned 13,509,973 shares in the company, valued at $16,211,967.60. This represents a 91.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the completion of the transaction, the insider directly owned 6,459,973 shares of the company’s stock, valued at $8,591,764.09. This represents a 53.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Tybourne Capital Management HK Ltd. increased its holdings in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after acquiring an additional 516,666 shares during the last quarter. Acadian Asset Management LLC boosted its position in Zentalis Pharmaceuticals by 4.7% during the second quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock worth $3,241,000 after purchasing an additional 124,985 shares during the period. Savant Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at $59,000. Public Employees Retirement System of Ohio increased its holdings in shares of Zentalis Pharmaceuticals by 351.7% in the second quarter. Public Employees Retirement System of Ohio now owns 36,700 shares of the company’s stock valued at $43,000 after purchasing an additional 28,576 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at about $38,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.